The months-long bidding war for obesity drugmaker Metsera came to an end late Friday, but not before federal regulators ...
The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...
Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...
Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...
Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...
The Daily Overview on MSN
Pfizer buys Metsera for $10B after obesity drug bidding war
Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...
Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...
Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...
On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...
That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...
The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...
At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback